Free Trial
NASDAQ:AARD

Aardvark Therapeutics (AARD) Stock Price, News & Analysis

Aardvark Therapeutics logo
$13.92 +0.40 (+2.96%)
As of 07/3/2025 01:00 PM Eastern

About Aardvark Therapeutics Stock (NASDAQ:AARD)

Key Stats

Today's Range
$13.44
$13.96
50-Day Range
$8.74
$15.76
52-Week Range
$4.88
$19.58
Volume
10,562 shs
Average Volume
79,916 shs
Market Capitalization
$302.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.00
Consensus Rating
Buy

Company Overview

Receive AARD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aardvark Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AARD Stock News Headlines

Analysts Set Expectations for AARD Q2 Earnings
I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
Trending Stocks By Analyst’s for this Week - The Globe and Mail
Aardvark Therapeutics (NASDAQ:AARD) Now Covered by HC Wainwright
See More Headlines

AARD Stock Analysis - Frequently Asked Questions

Aardvark Therapeutics' stock was trading at $13.30 at the beginning of the year. Since then, AARD shares have increased by 4.7% and is now trading at $13.92.

Aardvark Therapeutics, Inc. (NASDAQ:AARD) issued its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by $0.01.

Aardvark Therapeutics (AARD) raised $100 million in an initial public offering on Friday, February 14th 2025. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets acted as the underwriters for the IPO.

Aardvark Therapeutics's lock-up period expires on Tuesday, August 12th. Aardvark Therapeutics had issued 5,888,000 shares in its public offering on February 13th. The total size of the offering was $94,208,000 based on an initial share price of $16.00. After the expiration of Aardvark Therapeutics' lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Shares of AARD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/14/2025
Today
7/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AARD
Previous Symbol
NASDAQ:AARD
Web
N/A
Fax
N/A
Employees
18
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$33.00
High Stock Price Target
$50.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+137.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$302.06 million
Optionable
N/A
Beta
N/A
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:AARD) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners